These findings position CHIT1 as a promising CSF biomarker for monitoring therapeutic efficacy in pediatric SMA, warranting further validation in larger cohorts to confirm its predictive value [84]. The gene discussed is CHIT1; the disease is proximal spinal muscular atrophy.